BACKGROUND: Many breast cancer patients experience arthralgia symptoms during aromatase inhibitor (AI) treatment, which leads to poor compliance and a lower quality of life. OBJECTIVE: The research questions of this study were as follows: (1) What is the incidence of arthralgia during AI treatment in early breast cancer patients, (2) what is the impact of AI-associated arthralgia on hand function, daily activities, and AI adherence, and (3) does the healthcare provider recognize AI-associated arthralgia as relevant in clinical practice? METHODS: A total of 57 breast cancer patients of a University Breast Cancer Clinic participated in this study. Each patient completed a questionnaire, performed 2 function tests (goniometry of the wrist and a handgrip strength measurement), and consented to a review of the medical chart. RESULTS: Forty-two breast cancer patients (74%) reported symptoms of arthralgia. All patients with arthralgia symptoms experienced an impact on their daily activities, and 65% had a decrease in hand and finger function. Sixty-nine percent of all patients were fully adherent in their medicine treatment. In 26% of cases with arthralgia, the symptoms were not reported in the medical chart. CONCLUSION: Given the large number of patients with AI-associated arthralgia and its impact on daily life and functioning, it is of great importance to improve the recognition and care of arthralgia symptoms during AI treatment. IMPLICATIONS FOR PRACTICE: Oncology nurses could play an important role in assessment of modifiable risk factors, providing lifestyle advice and support in coping.
BACKGROUND: Many breast cancerpatients experience arthralgia symptoms during aromatase inhibitor (AI) treatment, which leads to poor compliance and a lower quality of life. OBJECTIVE: The research questions of this study were as follows: (1) What is the incidence of arthralgia during AI treatment in early breast cancerpatients, (2) what is the impact of AI-associated arthralgia on hand function, daily activities, and AI adherence, and (3) does the healthcare provider recognize AI-associated arthralgia as relevant in clinical practice? METHODS: A total of 57 breast cancerpatients of a University Breast Cancer Clinic participated in this study. Each patient completed a questionnaire, performed 2 function tests (goniometry of the wrist and a handgrip strength measurement), and consented to a review of the medical chart. RESULTS: Forty-two breast cancerpatients (74%) reported symptoms of arthralgia. All patients with arthralgia symptoms experienced an impact on their daily activities, and 65% had a decrease in hand and finger function. Sixty-nine percent of all patients were fully adherent in their medicine treatment. In 26% of cases with arthralgia, the symptoms were not reported in the medical chart. CONCLUSION: Given the large number of patients with AI-associated arthralgia and its impact on daily life and functioning, it is of great importance to improve the recognition and care of arthralgia symptoms during AI treatment. IMPLICATIONS FOR PRACTICE: Oncology nurses could play an important role in assessment of modifiable risk factors, providing lifestyle advice and support in coping.
Authors: Rebecca A Shelby; Sara N Edmond; Anava A Wren; Francis J Keefe; Jeffrey M Peppercorn; Paul K Marcom; Kimberly L Blackwell; Gretchen G Kimmick Journal: Support Care Cancer Date: 2014-05-13 Impact factor: 3.603
Authors: Rebecca A Shelby; Caroline S Dorfman; Hayden B Bosworth; Francis Keefe; Linda Sutton; Lynda Owen; Leonor Corsino; Alaattin Erkanli; Shelby D Reed; Sarah S Arthur; Tamara Somers; Nadine Barrett; Scott Huettel; Juan Marcos Gonzalez; Gretchen Kimmick Journal: Contemp Clin Trials Date: 2018-11-22 Impact factor: 2.226
Authors: Caitlin C Murphy; L Kay Bartholomew; Melissa Y Carpentier; Shirley M Bluethmann; Sally W Vernon Journal: Breast Cancer Res Treat Date: 2012-06-12 Impact factor: 4.872
Authors: Polly Niravath; Susan G Hilsenbeck; Tao Wang; Sao Jiralerspong; Julie Nangia; Anne Pavlick; Foluso Ademuyiwa; Ashley Frith; Cynthia Ma; Haeseong Park; Caron Rigden; Rama Suresh; Matthew Ellis; C Kent Osborne; Mothaffar F Rimawi Journal: Breast Cancer Res Treat Date: 2019-06-19 Impact factor: 4.872
Authors: Andrew Ernst; Kathryn E Flynn; Elizabeth M Weil; Bradley H Crotty; Sailaja Kamaraju; Nicole Fergestrom; Joan Neuner Journal: Clin Breast Cancer Date: 2020-07-22 Impact factor: 3.225